CAR

Avis Budget Group, Inc.
$161.49
+0.92 (+0.57%)
Mkt Cap 5.67B
Volume 41,392
52W Range 85.96-847.7
Sector Industrials
Beta 1.90
EPS (TTM) -18.93
P/E Ratio -5.08
Revenue (TTM) 11.75B
Rev Growth (5Y) +16.6%
EPS Growth (5Y) N/A
AlphaVal · Fair Value
What we estimate one share is worth
$142.27
Overvalued weak signal
12.0% above fair value
Modeled from cash flows & growth.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 11.65B 11.79B 12.01B 11.99B 9.31B 5.40B 9.17B 9.12B 8.85B 8.66B 8.50B 8.48B
Net Income (889.00M) (1.82B) 1.63B 2.76B 1.28B (684.00M) 302.00M 165.00M 361.00M 163.00M 313.00M 245.00M
EPS -25.26 -51.23 42.61 58.44 19.80 -9.70 4.02 2.08 4.32 1.78 3.02 2.32
Free Cash Flow (11.98B) (6.54B) (11.63B) 576.00M (2.59B) 3.95B (91.00M) (563.00M) 513.00M 482.00M 137.00M 188.00M
FCF / Share -340.28 -184.34 -303.66 12.18 -39.97 56.01 -1.21 -7.10 6.15 5.24 1.32 1.78
Operating CF 3.30B 3.52B 3.83B 4.71B 3.49B 691.00M 2.59B 2.61B 2.65B 2.63B 2.58B 2.58B
Total Assets 32.19B 29.95B 33.42B 25.93B 22.60B 17.54B 23.93B 19.23B 17.84B 17.79B 17.85B 17.02B
Total Debt 31.17B 26.04B 26.45B 20.92B 17.80B 13.66B 17.12B 13.78B 12.82B 12.40B 12.32B 11.54B
Cash & Equiv 519.00M 537.00M 559.00M 572.00M 537.00M 693.00M 689.00M 620.00M 618.00M 490.00M 452.00M 624.00M
Book Value (3.13B) (2.33B) (349.00M) (703.00M) (220.00M) (155.00M) 656.00M 414.00M 573.00M 221.00M 439.00M 665.00M
Return on Equity N/A N/A N/A N/A N/A N/A 0.46 0.40 0.63 0.74 0.71 0.37
CAR News
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Jul 15, 2026 03:00 AM · globenewswire.com
Avis Budget Group to Announce Second Quarter 2026 Results on July 28, 2026
Jul 13, 2026 01:32 PM · globenewswire.com
Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
Jul 13, 2026 05:00 AM · gurufocus.com
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Jul 06, 2026 04:30 AM · prnewswire.com
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Jul 06, 2026 04:30 AM · globenewswire.com
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
Jul 06, 2026 03:15 AM · seekingalpha.com
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Jul 04, 2026 06:10 AM · seekingalpha.com
Strong Car Rental Demand Aids Avis Budget Group Amid Low Liquidity
Jul 03, 2026 06:36 AM · zacks.com
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Jun 29, 2026 06:35 AM · benzinga.com
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Jun 26, 2026 05:10 AM · prnewswire.com